JP2020514286A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514286A5
JP2020514286A5 JP2019535891A JP2019535891A JP2020514286A5 JP 2020514286 A5 JP2020514286 A5 JP 2020514286A5 JP 2019535891 A JP2019535891 A JP 2019535891A JP 2019535891 A JP2019535891 A JP 2019535891A JP 2020514286 A5 JP2020514286 A5 JP 2020514286A5
Authority
JP
Japan
Prior art keywords
raav
promoter
suspension
enhancer
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019535891A
Other languages
English (en)
Japanese (ja)
Other versions
JP7128190B2 (ja
JP2020514286A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/068919 external-priority patent/WO2018126116A1/en
Publication of JP2020514286A publication Critical patent/JP2020514286A/ja
Publication of JP2020514286A5 publication Critical patent/JP2020514286A5/ja
Application granted granted Critical
Publication of JP7128190B2 publication Critical patent/JP7128190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019535891A 2016-12-30 2017-12-29 ウィルソン病を処置するための遺伝子療法 Active JP7128190B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662440659P 2016-12-30 2016-12-30
US62/440,659 2016-12-30
US201762473656P 2017-03-20 2017-03-20
US62/473,656 2017-03-20
PCT/US2017/068919 WO2018126116A1 (en) 2016-12-30 2017-12-29 Gene therapy for treating wilson's disease

Publications (3)

Publication Number Publication Date
JP2020514286A JP2020514286A (ja) 2020-05-21
JP2020514286A5 true JP2020514286A5 (enExample) 2021-01-28
JP7128190B2 JP7128190B2 (ja) 2022-08-30

Family

ID=62710046

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019535891A Active JP7128190B2 (ja) 2016-12-30 2017-12-29 ウィルソン病を処置するための遺伝子療法

Country Status (9)

Country Link
US (2) US11473106B2 (enExample)
EP (2) EP3562514A4 (enExample)
JP (1) JP7128190B2 (enExample)
KR (2) KR102604096B1 (enExample)
CN (1) CN110290814A (enExample)
BR (1) BR112019013245A2 (enExample)
CA (1) CA3048044A1 (enExample)
MX (1) MX2019007873A (enExample)
WO (1) WO2018126116A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019007873A (es) * 2016-12-30 2019-11-18 Univ Pennsylvania Terapia génica para tratar la enfermedad de wilson.
SG11202004926WA (en) 2017-12-01 2020-06-29 Encoded Therapeutics Inc Engineered dna binding proteins
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
US20190256867A1 (en) 2018-02-01 2019-08-22 Homology Medicines, Inc. Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
CN112041437A (zh) 2018-02-19 2020-12-04 同源药物公司 用于恢复f8基因功能的腺相关病毒组合物和其使用方法
JP2022513318A (ja) 2018-10-01 2022-02-07 ウルトラジェニックス ファーマシューティカル インコーポレイテッド プロピオン酸血症を処置するための遺伝子治療
WO2020102723A1 (en) * 2018-11-16 2020-05-22 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
PL3906066T3 (pl) * 2019-01-04 2024-09-02 Ultragenyx Pharmaceutical Inc. Konstrukty do terapii genowej do leczenia choroby wilsona
BR112021024055A2 (pt) 2019-05-29 2022-02-08 Encoded Therapeutics Inc Composições e métodos para a regulação seletiva de gene
CN111088285B (zh) * 2019-08-15 2021-12-28 北京锦篮基因科技有限公司 携带atp7b基因表达框及变异体的aav载体及应用
WO2021107647A1 (ko) * 2019-11-26 2021-06-03 한국생명공학연구원 단백질 발현용 mrna 구조체 및 이의 용도
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復pah基因功能的腺相關病毒組成物及其使用方法
EP4284335A1 (en) 2021-02-01 2023-12-06 RegenxBio Inc. Gene therapy for neuronal ceroid lipofuscinoses
US20240307553A1 (en) * 2021-04-01 2024-09-19 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
CN115216481A (zh) * 2021-04-21 2022-10-21 四川至善唯新生物科技有限公司 一种表达量提高的截短型atp7b基因及其应用
TW202323528A (zh) * 2021-10-18 2023-06-16 美商邏輯生物療法公司 用於治療威爾森氏病之基因療法
US20250320509A1 (en) * 2022-05-23 2025-10-16 The Johns Hopkins University Compositions and methods for treating wilson's disease
CN115216533A (zh) * 2022-06-30 2022-10-21 湖南家辉生物技术有限公司 一种用于诊断威尔逊病的生物标志物、扩增引物组、检测试剂及应用
WO2024183769A1 (en) * 2023-03-06 2024-09-12 Lingyi Biotech Co., Ltd. A truncated atp7b and the use thereof
WO2024193638A1 (en) * 2023-03-22 2024-09-26 Skyline Therapeutics (Shanghai) Co., Ltd. Recombinant aav for the gene therapy of wilson disease
US20240360431A1 (en) * 2023-04-30 2024-10-31 Sichuan Real&Best Biotech Co., Ltd. Engineered alpha-galactosidase a (a-gal a) peptides and functional variants thereof and associated methods of treating fabry disease
CN120882865A (zh) * 2023-07-28 2025-10-31 凌意(杭州)生物科技有限公司 用于治疗威尔逊病的多核苷酸
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease
CN117947035A (zh) * 2024-03-25 2024-04-30 上海凌医生物科技有限公司 一种增强基因表达的启动子

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002350039A1 (en) 2001-10-29 2003-05-12 Renovis, Inc. Method for isolating cell-type specific mrnas
DE10156121A1 (de) 2001-11-16 2003-05-28 Wolfgang Stremmel Somatische Gentherapie mit Vektoren, die einen verkürzten metallsensitiven Promotor besitzen, zur Behandlung des Morbus Wilson sowie anderer Erkrankungen, die mit Veränderungen im Metallstoffwechsel einhergehen, wie z.B. Alzheimer-Erkrankung
WO2003052051A2 (en) 2001-12-17 2003-06-26 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences
EP1660970A4 (en) 2003-08-01 2007-02-14 Dna Twopointo Inc SYSTEMS AND METHODS FOR BIOPOLYMER TECHNOLOGY
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
DK3211085T3 (da) 2003-09-30 2021-06-21 Univ Pennsylvania Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
SG10201908848RA (en) 2010-03-29 2019-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
WO2012097826A2 (en) 2011-01-21 2012-07-26 Aarhus Universitet Crystal structure of a type ib p-type atpase
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
WO2013123503A1 (en) 2012-02-17 2013-08-22 The Children's Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
EP2834259A4 (en) 2012-04-02 2016-08-24 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
RU2745567C2 (ru) * 2014-12-17 2021-03-29 Фундасион Пара Ла Инвестигасион Медика Апликада Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
US11118238B2 (en) * 2014-12-17 2021-09-14 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson's disease and other conditions
GB201508026D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Capsid
WO2017100676A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
MX2019007873A (es) 2016-12-30 2019-11-18 Univ Pennsylvania Terapia génica para tratar la enfermedad de wilson.
WO2020102723A1 (en) 2018-11-16 2020-05-22 Encoded Therapeutics, Inc. Compositions and methods for treating wilson's disease
PL3906066T3 (pl) 2019-01-04 2024-09-02 Ultragenyx Pharmaceutical Inc. Konstrukty do terapii genowej do leczenia choroby wilsona

Similar Documents

Publication Publication Date Title
JP2020514286A5 (enExample)
JP2019513794A5 (enExample)
RU2018136611A (ru) Генная терапия для лечения гемофилии a
JP7374119B2 (ja) 減少した肝臓向性を有するAAV9とAAVrh74とのハイブリッド組換えアデノ随伴ウイルス血清型
JP2017512466A5 (enExample)
JP2020510428A5 (enExample)
JP2018537984A5 (enExample)
FI3684423T3 (fi) Adenoassesioidun viruksen kapsidivariantteja ja niiden käyttömenetelmiä
JP2020519292A5 (enExample)
US10413598B2 (en) Factor IX gene therapy
ES2640586T3 (es) Secuencias del factor VIII
JP2018531609A5 (enExample)
JP2016512683A5 (enExample)
JP2014512171A5 (enExample)
JP2019513393A5 (enExample)
JP2018520997A5 (enExample)
JP2022522995A (ja) Aav粒子を生成するための方法及びシステム
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2019513779A5 (enExample)
JP2019503649A5 (enExample)
JP2018522529A5 (enExample)
TW201706412A (zh) Fabry氏病基因療法
EP4378487A3 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
RU2015144234A (ru) Композиции и способы лечения mps1
JP2018506261A5 (enExample)